Susanna Y. Cheng

Pembrolizumab plus Chemotherapy in Metastatic Non–Small-Cell Lung Cancer

Leena Gandhi, Delvys Rodríguez‐Abreu, Shirish M. Gadgeel et al. · New England Journal of Medicine · 2018 · 6.6K citations · Full text

Medicine, Oncology, Pharmacology +16

Pemetrexed plus platinum with or without pembrolizumab in patients with previously untreated metastatic nonsquamous NSCLC: protocol-specified final analysis from KEYNOTE-189

Delvys Rodríguez‐Abreu, Steven Powell, Maximilian J. Hochmair et al. · Annals of Oncology · 2021 · 418 citations · Full text

Medicine, Oncology, Pharmacology +11

Amivantamab plus Chemotherapy in NSCLC with <i>EGFR</i> Exon 20 Insertions

Caicun Zhou, Kejing Tang, Byoung Chul Cho et al. · New England Journal of Medicine · 2023 · 347 citations

Medicine, Oncology, Pharmacology +14

Patient-reported outcomes following pembrolizumab or placebo plus pemetrexed and platinum in patients with previously untreated, metastatic, non-squamous non-small-cell lung cancer (KEYNOTE-189): a multicentre, double-blind, randomised, placebo-controlled, phase 3 trial

Marina Chiara Garassino, Shirish M. Gadgeel, Emilio Esteban et al. · The Lancet Oncology · 2020 · 213 citations

Medicine, Oncology, Pharmacology +14

Ramucirumab plus docetaxel versus placebo plus docetaxel in patients with locally advanced or metastatic urothelial carcinoma after platinum-based therapy (RANGE): a randomised, double-blind, phase 3 trial

Daniel P. Petrylak, Ronald de Wit, Kim N. et al. · The Lancet · 2017 · 177 citations · Full text

Medicine, Oncology, Pharmacology +15